// App-Quantinova.ai

TPS7052 : V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.

Researchers

Presenter

  • Laura Agresta

Principal Investigators

  • Maureen Megan O'Brien

  • Eric Justin O'Brien

  • Robin Elizabeth Norris

  • Erin Haag Breese

  • Karen Cristly Burns

  • Benjamin Mizukawa

  • Thomas D Ryan

  • Pankaj B Desai

  • A.a. Vinks

  • H. Leighton Grimes

  • Michael Absalon

  • John Peter Perentesis

Medical Centers

  • Michigan State University College of Human Medicine, Grand Rapids, MI

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • Rainbow Babies and Children's Hospital, Cleveland, OH

  • Cincinnati Children's Hospital Medical Center,

  • University of Cincinnati, College of Pharmacy, Cincinnati, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Acute lymphoblastic leukemia

  • Congestive heart failure

  • Acute Leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • daunorubicin + cytarabine

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • NCT02642965

  • NCT01943682

  • NCT03826992

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved